PL1897558T3 - Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu - Google Patents

Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu

Info

Publication number
PL1897558T3
PL1897558T3 PL06747305T PL06747305T PL1897558T3 PL 1897558 T3 PL1897558 T3 PL 1897558T3 PL 06747305 T PL06747305 T PL 06747305T PL 06747305 T PL06747305 T PL 06747305T PL 1897558 T3 PL1897558 T3 PL 1897558T3
Authority
PL
Poland
Prior art keywords
hexadecyloxy
benzoxazin
methyl
solid preparation
preparation
Prior art date
Application number
PL06747305T
Other languages
English (en)
Inventor
H Suzuki
Y Ebisawa
T Yoshinari
Original Assignee
Norgine Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norgine Bv filed Critical Norgine Bv
Publication of PL1897558T3 publication Critical patent/PL1897558T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06747305T 2005-06-09 2006-06-09 Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu PL1897558T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005170172 2005-06-09
PCT/JP2006/312078 WO2006132440A1 (ja) 2005-06-09 2006-06-09 固形製剤
EP06747305.8A EP1897558B1 (en) 2005-06-09 2006-06-09 Solid preparation of 2-hexadecyloxy-6-methyl-4h-3,1-benzoxazin-4-one

Publications (1)

Publication Number Publication Date
PL1897558T3 true PL1897558T3 (pl) 2014-01-31

Family

ID=37498616

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06747305T PL1897558T3 (pl) 2005-06-09 2006-06-09 Stały preparat 2-heksadecyloksy-6-metylo-4H-3,1-benzoksazyn-4-onu

Country Status (10)

Country Link
US (2) US20090208584A1 (pl)
EP (1) EP1897558B1 (pl)
JP (1) JP5044398B2 (pl)
CA (1) CA2611451C (pl)
DK (1) DK1897558T3 (pl)
ES (1) ES2434072T3 (pl)
PL (1) PL1897558T3 (pl)
PT (1) PT1897558E (pl)
SI (1) SI1897558T1 (pl)
WO (1) WO2006132440A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
JP2010529142A (ja) 2007-06-08 2010-08-26 アドレネクス・ファーマシューティカルズ，インコーポレイテッド アドレナリン調節異常症を治療する徐放性の製剤および方法
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
EP2233129B1 (en) * 2007-12-28 2014-05-07 Sawai Pharmaceutical Co., Ltd. Oral cavity disintegrating tablet and method of producing the same
PE20110551A1 (es) * 2008-07-31 2011-09-02 Takeda Pharmaceutical Composicion farmaceutica solida que contiene un derivado de bencimidazol y un diuretico
AR073380A1 (es) * 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
JP2010254623A (ja) 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
BR112012001959A2 (pt) * 2009-07-28 2016-03-15 Takeda Pharmaceutical comprimido,e, método para reproduzir um comprimido
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
ES2524896T3 (es) 2010-06-16 2014-12-15 Takeda Pharmaceutical Company Limited Cristal de compuesto de amida
EP2729145A4 (en) * 2011-07-07 2014-12-10 Arqule Inc PYRROLOCHINOLINYLPYRROLIDIN-2,5-DION FORMULATIONS AND METHOD FOR THEIR PREPARATION AND USE
WO2013057805A1 (ja) * 2011-10-19 2013-04-25 日本曹達株式会社 尿石防止剤
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
AU2012101841A4 (en) * 2011-12-23 2013-01-17 Norgine Bv Compositions comprising cetilistat
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
WO2013122260A1 (en) * 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
JP5686452B2 (ja) * 2013-03-01 2015-03-18 塩野義製薬株式会社 イルベサルタンを含有する錠剤
CN104971051A (zh) * 2014-04-11 2015-10-14 刘小斌 一种赛利司他片及制备方法
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB224671A (en) 1923-10-03 1924-11-20 Ismay Annie Fownes Improvements in and relating to wire-netting fencing
JPS5116491B2 (pl) 1971-10-08 1976-05-25
US4623588A (en) * 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
JP2842244B2 (ja) * 1993-09-21 1998-12-24 武田薬品工業株式会社 イデベノン粒剤およびその製造法
JP3532999B2 (ja) * 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
JPH10182436A (ja) * 1996-10-31 1998-07-07 Takeda Chem Ind Ltd 固形医薬製剤
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US6172095B1 (en) * 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
JP3926888B2 (ja) * 1997-05-27 2007-06-06 株式会社カネカ コレステロール低下剤
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
KR100536783B1 (ko) * 1998-07-28 2005-12-14 다케다 야쿠힌 고교 가부시키가이샤 급속 붕해성 고체 제제
BR9912980B1 (pt) 1998-08-14 2013-10-22 Composição farmacêutica administrável oralmente, tablete de mascar contendo a mesma e utilização da mesma
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
JP2000273039A (ja) * 1999-01-20 2000-10-03 Taisho Pharmaceut Co Ltd 口腔内崩壊性組成物
US6740339B1 (en) * 1999-06-18 2004-05-25 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
WO2001025228A1 (en) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Amine derivatives
ES2225252T3 (es) 1999-11-10 2005-03-16 Takeda Chemical Industries, Ltd. Compuestos n-heterociclicos de 5 miembros con actividad hipoglucemica e hipolipidemica.
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
JP2001316249A (ja) * 2000-05-11 2001-11-13 Lion Corp 錠剤型医薬組成物
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP2001335469A (ja) * 2000-05-26 2001-12-04 Lion Corp 固体製剤の製造方法
CN100423715C (zh) * 2000-07-28 2008-10-08 霍夫曼-拉罗奇有限公司 新型药物组合物
US6967212B2 (en) * 2001-05-30 2005-11-22 Bristol-Myers Squibb Company Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
US20050003001A1 (en) * 2001-11-07 2005-01-06 Hisami Yamaguchi Method for improving dissolution of poorly dispersible medicaments
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
WO2004069834A1 (ja) * 2003-02-07 2004-08-19 Takeda Pharmaceutical Company Limited 三環性化合物、その製造方法および用途
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
JP2005170172A (ja) 2003-12-10 2005-06-30 Ogura Clutch Co Ltd 車両室内用遮蔽装置
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations

Also Published As

Publication number Publication date
US20090208584A1 (en) 2009-08-20
DK1897558T3 (da) 2013-12-09
CA2611451A1 (en) 2006-12-14
ES2434072T3 (es) 2013-12-13
JP5044398B2 (ja) 2012-10-10
WO2006132440A1 (ja) 2006-12-14
JPWO2006132440A1 (ja) 2009-01-08
EP1897558A1 (en) 2008-03-12
US20140178477A1 (en) 2014-06-26
PT1897558E (pt) 2013-11-06
EP1897558A4 (en) 2012-09-12
EP1897558B1 (en) 2013-09-04
CA2611451C (en) 2014-04-22
SI1897558T1 (sl) 2014-03-31

Similar Documents

Publication Publication Date Title
IL191655A0 (en) Novel compounds, their preparation and use
IL191774A0 (en) Solid preparation
EP2050010A4 (en) Ad-hoc simple configuration
SI1897558T1 (sl) Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
IL184036A0 (en) Preparation of rosuvastatin
IL188330A0 (en) Processes for the preparation of
AP2255A (en) Irinotecan preparation.
ZA200805646B (en) Controlled release solid preparation
EP1942734A4 (en) PREPARATION OF THE APREPITANT
PT2468732E (pt) 1h-quinazolino-2,4-dionas e sua utilização como ligandos dos receptores ampa
ZA200707962B (en) Novel resorcinol derivatives
ZA200805706B (en) Controlled release solid preparation
EP1907710A4 (en) MEANS OF CONSTRUCTION
EP1912499A4 (en) PREPARATION OF MONTELUKAST
ZA200801208B (en) Anti-malarial composition
ZA200801708B (en) Synthesis of 1±-fluoro-25-hydroxy-16-23E-diene-26,27-bishomo-20-EPI-cholecalciferol
GB0504018D0 (en) Quinazoline derivatives
EP1880287A4 (en) NETWORKING OF TWO COMPANIES
IL187948A0 (en) Preparation of rosuvastatin
IL189681A0 (en) Sustained-release preparation
GB0519954D0 (en) Lockerbank construction
EP1947248A4 (de) Erdbebensichere konstruktion
GB0712671D0 (en) Compounds, compositions and processes
EP1915380A4 (en) PROCESS FOR THE SYNTHESIS OF N, N'-DISUBSTITUTED OXABISPIDINES
GB0508439D0 (en) Design of structural elements